News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients
20 April 2020
Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)
24 March 2020
National Center for Research and Development (NCBR) funds OncoArendi Therapeutics’ new research platform of innovative anticancer drugs targeting deubiquitinase proteins.
31 January 2020
First clinical proof-of-concept for arginase inhibitors in cancer immunotherapy
1 October 2019
OncoArendi Therapeutics at the 2019 BIO International Convention in USA
31 May 2019
Events & Presentations
Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada
27 February 2020
ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA
4 September 2019
EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018
17 September 2018